drugset / Trial / NCT06994520

Efficacy of Topical Cannabidiol for Eczema

NCT06994520

Phase 2 Active not recruiting 60 enrolled Khon Kaen University
RandomizedParallel-groupTriple-blindTreatment

Summary

Itching is a common symptom encountered in general medical practice. It can cause significant discomfort, disrupt sleep, and impair patients' quality of life. Chronic pruritic skin conditions such as atopic dermatitis, nummular eczema, lichen simplex chronicus, and prurigo nodularis are frequently observed. The pathogenesis of these conditions remains incompletely understood, and effective long-term treatment options are limited. Current therapies include topical corticosteroids, topical calcineurin inhibitors, oral corticosteroids, and systemic immunosuppressants. However, these treatments are often associated with adverse effects, and the diseases tend to follow a chronic, relapsing course. Therefore, the investigators aim to investigate the efficacy and safety of topical cannabis extract in patients with chronic pruritic skin conditions.

Timeline

Start
2025-05-01
Primary completion
2026-05-01
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Triamcinolone Other / unclassified 0.1 %